

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/593,401	06/14/2000	Kailash Prasad	44892	9007
75	90 05/31/2002			~
Norris M Eades			EXAMINER	
Kirby Eades Ga P O Box 3432 S		RILEY, JEZIA		
Ottawa, ON K1P 6N9 CANADA			ART UNIT	PAPER NUMBER
			1637	
			DATE MAILED: 05/31/2002	3

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application	No.	Applicant(s)			
6 eve-*		09/593,401		PRASAD, KAILASH			
	Office Action Summary	Examiner		Art Unit			
		MAUPIN-	Riley	1637			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status							
1)⊠	Responsive to communication(s) filed on 17	<u>May 2002</u> .					
2a) <u></u> □	This action is FINAL . 2b)⊠ Th	nis action is n	on-final.				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. Disposition of Claims							
4)⊠ Claim(s) <u>1-5</u> is/are pending in the application.							
4	4a) Of the above claim(s) is/are withdrawn from consideration.						
5)	5) Claim(s) is/are allowed.						
6)⊠	☑ Claim(s) <u>1-5</u> is/are rejected.						
7) 🔲	7) Claim(s) is/are objected to.						
	Claim(s) are subject to restriction and/o	or election red	quirement.	Sharan Whenter SHARON N. THORNTON			
9) The specification is objected to by the Examiner.							
10) 🔲 🏾	10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
11) 🗌 7	11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.						
	If approved, corrected drawings are required in re	ply to this Offic	ce action.				
12)☐ The oath or declaration is objected to by the Examiner.							
Priority under 35 U.S.C. §§ 119 and 120							
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a)[a) ☐ All b) ☐ Some * c) ☐ None of:						
	1. Certified copies of the priority documents have been received.						
	2. Certified copies of the priority documents have been received in Application No						
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 							
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).							
a) The translation of the foreign language provisional application has been received. 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.							
Attachment(s)							
2) Notice	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s) 2	4		nmmary (PTO-413) Paper No(s) ormal Patent Application (PTO-152)			
J.S. Patent and Tr PTO-326 (Rev		ction Summary		Part of Paper No. 5			

Application/Control Number: 09/593,401

Art Unit: 1637

DETAILED ACTION

Claim Rejections - 35 USC § 103

- 1. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 2. Claims 1-5 are rejected under 35 U.S.C. 103(a) as being unpatentable over over Clark et al. (5,837,256) in view of Talom et al. (Life Sciences, 1999, Vol. 64, No.16; pp. 1415-1425).

Clark et al. discloses a method of treatment of lupus nephritis which comprises administering to a patient an effective amount of secoisolariciresinol or secoisolariciresinol diglucoside (SDG) in substantially pure form. Lupus varies greatly in severity from mild cases requiring minimal intervention to those in which significant damage occurs to vital organs such as lungs, kidneys, heart and brain.

Talom et al. discloses that high flaxseed diet restores endothelial function in the mesenteric arterial bed of spontaneously hypertensive rats (pages 1421-1424).

Therefore it would have been obvious at the time the invention was made to use SDG (which is from flaxseed) to prevent hypertension in human since flaxseed diet have been suggested to contributes to an increased responsiveness to vasodilator influences and that this effect is greater in the hypertensive animal relative to its normotensive counterpart (Talom page 1422).

Application/Control Number: 09/593,401

Art Unit: 1637

3. The references in PTO-1449 have been lined through because they missing

publication dates.

4. Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Jezia Riley whose telephone number is 703-305-6855.

The examiner can normally be reached on 9:30AM - 5:00PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Gary Benzion can be reached on 703-308-1119. The fax phone numbers

for the organization where this application or proceeding is assigned are 703-305-3014

for regular communications and 703-308-4242 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or

proceeding should be directed to the receptionist whose telephone number is 703-308-

0196.

May 24, 2002

JEZIA HILEY

Page 3